Post-EHA 2026 MPN Highlights

Featuring presentations & discussions on selected MPN abstracts from the 31st Congress of the European Hematology Association (EHA).  

Chair: Claire Harrison | Moderators: John Mascarenhas & Jean-Jacques Kiladjian

Preliminary Agenda (subject to change)

Session 1: Novel treatment approaches for essential thrombocythemia & polycythemia vera  

Early versus delayed initiation of ropeginterferon alfa-2b in high-risk essential thrombocythaemia: Two-year results from the Phase 3 SURPASS-ET study (Abstract S219) | Speaker: Harinder Gill

Mutant calreticulin-specific monoclonal antibody, INCA033989, is well tolerated and achieves rapid and sustained hematologic and molecular responses in patients with essential thrombocythemia (ET) (Abstract PS1983) | Speaker: John Mascarenhas

Benefit of rusfertide maintained in patients (pts) with low-risk or high-risk polycythemia vera (PV): Efficacy and safety subgroup analysis from the randomized controlled Phase 3 VERIFY study (Abstract PF892) | Speaker: Valentin Garcia Gutierrez

Divesiran, a novel galnac conjugated siRNA, reduces phlebotomies, improves iron stores and symptoms in polycythemia vera patients in SANRECO Phase 1 study (Abstract PF886) | Speaker: Marina Kremyanskaya

Panel discussion 

Session 2: Latest in targeted therapies for myelofibrosis 

Results of AJX-101, a Phase 1 clinical trial of the type II JAK2 inhibitor AJ1-11095, in patients with myelofibrosis who have been failed by a type I JAK2 inhibitor (Abstract S218) | Speaker: John Mascarenhas

Mutant calreticulin–specific monoclonal antibody, INCA033989, is well tolerated and achieves robust spleen, anemia, and molecular responses in patients (pts) with myelofibrosis (MF) (Abstracts S216 & PF884) | Speaker: Claire Harrison

RALLY-MF: Initial efficacy of a Phase 2 study of DISC-0974, an anti-hemojuvelin antibody, to treat anemia in myelofibrosis (Abstract S306) | Speaker: Naseema Gangat

Selinexor plus ruxolitinib in Janus kinase inhibitor–naïve myelofibrosis: Phase 3 SENTRY trial (Abstract LB5002) | Speaker: Claire Harrison

Panel discussion 

Session 3: Updates in second-line myelofibrosis management 

Investigational PIM1 inhibitor nuvisertib in combination with momelotinib showed promising clinical activity in patients with myelofibrosis and anemia: Data from an ongoing global Phase 1/2 study (Abstract PS1985) | Speaker: TBC

Efficacy and safety of luspatercept in patients with myelofibrosis on Janus kinase inhibitors who require red blood cell transfusions: Primary analysis of the Phase 3 INDEPENDENCE trial (Abstract S215) | Speaker: Francesco Passamonti

Panel discussion 

Session 4: Novel approaches for MPNs, MPN-associated disease and mastocytosis 

Development of a G6B directed antibody drug conjugate for the treatment of myeloproliferative neoplasms (Abstract S210) | Speaker: Adam Mead

Measurable residual disease in myelofibrosis: Clonal correlates from a prospective Phase II study (Abstract PF913) | Speaker: Nico Gagelmann

Antithrombotic and cytoreduction strategies in myeloproliferative neoplasm-associated splanchnic vein thrombosis: A retrospective study from the French intergroup of myeloproliferative neoplasms (Abstract PS1991) | Speaker: TBC

Efficacy and safety of bezuclastinib in patients with advanced systemic mastocytosis: primary results from the APEX study (Abstract S217) | Speaker: Daniel Deangelo

Panel discussion 

Conclusions and webinar close